Publication:
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study.

Simple item page
dc.contributor.authorRodriguez-Arboli, Eduardo
dc.contributor.authorMartinez-Cuadron, David
dc.contributor.authorRodriguez-Veiga, Rebeca
dc.contributor.authorCarrillo-Cruz, Estrella
dc.contributor.authorGil-Cortes, Cristina
dc.contributor.authorSerrano-Lopez, Josefina
dc.contributor.authorBernal Del Castillo, Teresa
dc.contributor.authorMartinez-Sanchez, Maria Del Pilar
dc.contributor.authorRodriguez-Medina, Carlos
dc.contributor.authorVidriales, Belen
dc.contributor.authorBergua, Juan Miguel
dc.contributor.authorBenavente, Celina
dc.contributor.authorGarcia-Boyero, Raimundo
dc.contributor.authorHerrera-Puente, Pilar
dc.contributor.authorAlgarra, Lorenzo
dc.contributor.authorSayas-Lloris, Maria Jose
dc.contributor.authorFernandez, Rosa
dc.contributor.authorLabrador, Jorge
dc.contributor.authorLavilla-Rubira, Esperanza
dc.contributor.authorBarrios-Garcia, Manuel
dc.contributor.authorTormo, Mar
dc.contributor.authorSerrano-Maestro, Alfons
dc.contributor.authorSossa-Melo, Claudia Lucia
dc.contributor.authorGarcia-Belmonte, Daniel
dc.contributor.authorVives, Susana
dc.contributor.authorRodriguez-Gutierrez, Juan Ignacio
dc.contributor.authorAlbo-Lopez, Carmen
dc.contributor.authorGarrastazul-Sanchez, Maria Paz
dc.contributor.authorColorado-Araujo, Mercedes
dc.contributor.authorMariz, Jose
dc.contributor.authorSanz, Miguel Angel
dc.contributor.authorPerez-Simon, Jose Antonio
dc.contributor.authorMontesinos, Pau
dc.contributor.funderCM19/00194
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderCIBERONC
dc.contributor.groupPETHEMA (Programa Español de Tratamientos en Hematología) and GETH (Grupo Español de Trasplante Hematopoyético y Terapia Celular) Cooperative Groups
dc.date.accessioned2023-02-09T10:51:16Z
dc.date.available2023-02-09T10:51:16Z
dc.date.issued2020-12-24
dc.description.abstractAcute myeloid leukemia (AML) with intermediate risk cytogenetics (IRcyto) comprises a variety of biological entities with distinct mutational landscapes that translate into differential risks of relapse and prognosis. Optimal postremission therapy choice in this heterogeneous patient population is currently unsettled. In the current study, we compared outcomes in IRcyto AML recipients of autologous (autoSCT) (n = 312) or allogeneic stem cell transplantation (alloSCT) (n = 279) in first complete remission (CR1). Molecular risk was defined based on CEBPA, NPM1, and FLT3-ITD mutational status, per European LeukemiaNet 2017 criteria. Five-year overall survival (OS) in patients with favorable molecular risk (FRmol) was 62% (95% confidence interval [CI], 50-72) after autoSCT and 66% (95% CI, 41-83) after matched sibling donor (MSD) alloSCT (P = .68). For patients of intermediate molecular risk (IRmol), MSD alloSCT was associated with lower cumulative incidence of relapse (P
dc.description.sponsorshipSupported by a Río Hortega academic clinical fellowship (CM19/00194) from the Instituto de Salud Carlos III, Spain (E.R.A.). Additional funding has been provided by CIBERONC grants to J.P.S. (CB16/12/00480), M.M.S. (CB16/ 12/00369) and B.V. (CB16/12/00233).
dc.description.versionSi
dc.identifier.citationRodríguez-Arbolí E, Martínez-Cuadrón D, Rodríguez-Veiga R, Carrillo-Cruz E, Gil-Cortés C, Serrano-López J, et al. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study. Transplant Cell Ther. 2021 Apr;27(4):311.e1-311.e10
dc.identifier.doi10.1016/j.jtct.2020.12.029
dc.identifier.essn2666-6367
dc.identifier.pmid33836871
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.jtct.2020.12.029
dc.identifier.urihttp://hdl.handle.net/10668/17556
dc.issue.number4
dc.journal.titleTransplantation and cellular therapy
dc.journal.titleabbreviationTransplant Cell Ther
dc.language.isoen
dc.organizationHospital Universitario Puerta del Mar
dc.organizationHospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba-IMIBIC
dc.organizationHospital Universitario Regional de Málaga
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number10
dc.provenanceRealizada la curación de contenido 02/09/2024
dc.publisherElsevier
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.relation.projectIDCB16/12/00480
dc.relation.projectIDCB16/12/00369
dc.relation.projectIDCB16/12/00233
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S2666636721000051?via%3Dihub
dc.rights.accessRightsopen access
dc.subjectAcute myeloid leukemia
dc.subjectAllogeneic stem cell transplant
dc.subjectAutologous stem cell transplant
dc.subject.decsAnálisis citogenético
dc.subject.decsInducción de remisión
dc.subject.decsLeucemia mieloide aguda
dc.subject.decsNucleofosmina
dc.subject.decsTrasplante homólogo
dc.subject.decsTrasplante de células madre hematopoyéticas
dc.subject.meshCytogenetic Analysis
dc.subject.meshHematopoietic Stem Cell Transplantation
dc.subject.meshHumans
dc.subject.meshLeukemia, Myeloid, Acute
dc.subject.meshNucleophosmin
dc.subject.meshRemission Induction
dc.subject.meshTransplantation, Homologous
dc.titleLong-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number27
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Virgen del Rocío
Instituto de Investigación Biomédica de Sevilla (IBIS)
Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
SAS - Hospital Regional Universitario de Málaga
SAS - Hospital Universitario Puerta del Mar
SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía